MRNA Stock Eyes Next Leg As FDA Clears New Flu Shot

Moderna Inc. stocks have been trading up by 83.01 percent amid highly optimistic sentiment around its advancing mRNA vaccine pipeline.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading MRNA

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For MRNA Traders

FDA approval of mFLUSIVA gives Moderna a fourth U.S.‑approved product and targets a 2026–27 launch, expanding its respiratory vaccine lineup beyond COVID.
Q2 2026 for MRNA showed modest revenue growth and a narrower $1.97 loss per share, beating Wall Street expectations and tightening full‑year expense guidance.
Management is targeting up to 10% revenue growth in 2026 from 2025, with lower projected cost of sales at $1.7B and a more balanced U.S./international revenue mix.
A Phase 3 norovirus miss clipped one pipeline pillar, but oncology and rare disease programs at Moderna remain on track for pivotal data in 2026.
Goldman Sachs and Citi raised MRNA price targets to $67 and $60, signaling cautious optimism as the pipeline advances and guidance firms up.

Live Update At 07:48:06 EDT: On Wednesday, August 19, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 83.01%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRNA has been trading like a biotech rollercoaster, but there is structure in the chaos. On the daily chart, Moderna stock has climbed from the mid‑$50s in late July to the low‑$60s by 2026/08/18, with several strong pushes over $64. That tells traders dip‑buyers are still active on pullbacks.

Zoom in to the intraday action and you see classic momentum behavior. MRNA ripped from the mid‑$60s premarket to a spike above $110, then faded hard but held much higher than where it started. That sort of wide range shows aggressive day‑trading interest and heavy liquidity, ideal for short‑term setups.

Fundamentally, MRNA is still losing money. Q2 2026 showed a net loss of $782M and negative operating cash flow of $526M. Margins are sharply negative, with EBIT margin around -139% and profit margin even weaker. Yet Moderna still reported $1.94B in revenue over the trailing period, a 32.3% gross margin, and a strong balance sheet with $5.14B in cash and short‑term investments against modest debt.

More Breaking News

For traders, that mix—big cash, ongoing losses, and headline‑driven spikes—creates a classic news‑momentum play rather than a slow, steady compounder.

Why Traders Are Watching MRNA Now

The main new catalyst for MRNA is the FDA approval of mFLUSIVA, its mRNA‑1010 seasonal flu vaccine for adults 50+. This is not just another press release. It is Moderna’s fifth global product and fourth FDA‑approved product, with a U.S. launch targeted for the 2026–27 flu season. That gives traders a clearer line of sight to fresh revenue beyond the fading COVID tailwind.

For a company like Moderna, each approved shot changes the story. mFLUSIVA plugs directly into the existing respiratory franchise and supports management’s goal of up to 10% revenue growth in 2026 versus 2025. With cost‑of‑sales guidance cut to $1.7B from $1.8B and 2026 revenue expected to be roughly half U.S., half international, MRNA is shifting from a single‑product pandemic story into a diversified vaccine platform.

Q2 2026 results backed that narrative. MRNA beat expectations on both revenue and EPS, landing a smaller‑than‑feared $1.97 loss per share versus a $2.01 consensus. The company tightened operating expense guidance and improved its year‑end cash outlook, showing better cost control even while keeping R&D high at about $2.9B for 2026.

The pipeline is not all green lights. A key Phase 3 norovirus trial failed to hit early success criteria, which removes one upside chip from the table. But Moderna emphasized that oncology—especially intismeran/mRNA‑4157 with Merck—and rare disease programs are still on track for pivotal data in 2026. Add in the early‑stage Bundibugyo ebolavirus vaccine mRNA‑1469, backed by up to $50M from CEPI, and traders can see why the story still leans bullish, even with bumps.

Street reaction lines up with that balanced view. Goldman Sachs lifted its MRNA target to $67, Citi moved to $60, and UBS nudged to $50, all with Neutral ratings. Translation for traders: expectations are rising, but the crowd is not all‑in yet—prime territory for momentum around each new data point.

Conclusion

For active traders, MRNA is back in the spotlight for real reasons, not just meme‑style chatter. The FDA green light for mFLUSIVA locks in another commercial asset for the 2026–27 season and helps anchor Moderna’s long‑term revenue bridge. At the same time, Q2 numbers show that while Moderna remains unprofitable, execution is improving, cash burn is being managed, and the balance sheet still gives the company room to keep swinging.

The chart confirms that story. MRNA is attracting heavy premarket and intraday volume, with wide trading ranges that reward those who plan their entries and cut losses quickly. With multiple price‑target hikes, active pipeline headlines, and clear dates ahead for oncology and rare‑disease readouts, the stock offers plenty of catalysts for news‑driven moves. In this kind of fast tape, preparation and planning matter more than ever. As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.”

Traders still need to respect the risk. Negative margins, a big R&D budget, and binary trial outcomes can swing MRNA hard in both directions. That is exactly why it fits the playbook Tim Sykes teaches: “Volatility is opportunity, but only for traders who are prepared and disciplined.” This article is for educational and research purposes only, but if you are watching MRNA, treat it as a fast‑moving vehicle—powerful, but unforgiving if you stop paying attention.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!